Whilst it may not be a huge deal, we thought it was good to see that the Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Chairman of The Board, James Peyer, recently bought US$80k worth of stock, for US$4.02 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.
Sensei Biotherapeutics Insider Transactions Over The Last Year
The Chief R&D Officer, Robert Pierce, made the biggest insider sale in the last 12 months. That single transaction was for US$568k worth of shares at a price of US$7.13 each. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was at well above current price of US$3.79. So it may not shed much light on insider confidence at current levels. Robert Pierce was the only individual insider to sell shares in the last twelve months.
Happily, we note that in the last year insiders paid US$330k for 59.95k shares. But insiders sold 95.82k shares worth US$686k. Robert Pierce sold a total of 95.82k shares over the year at an average price of US$7.16. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership of Sensei Biotherapeutics
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Sensei Biotherapeutics insiders own about US$21m worth of shares. That equates to 18% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
What Might The Insider Transactions At Sensei Biotherapeutics Tell Us?
It's certainly positive to see the recent insider purchases. However, the longer term transactions are not so encouraging. The more recent transactions are a positive, but Sensei Biotherapeutics insiders haven't shown the sustained enthusiasm that we look for, although they do own a decent number of shares, overall. So they seem pretty well aligned, overall. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To that end, you should learn about the 4 warning signs we've spotted with Sensei Biotherapeutics (including 2 which are potentially serious).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.